Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Stock Information for Enveric Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enveric Biosciences Inc.

ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Enveric Biosciences Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.